

Fluticasone Furoate/Vilanterol: A Review of Its Use in C Disease

Drugs

74, 1509-1522

DOI: [10.1007/s40265-014-0269-6](https://doi.org/10.1007/s40265-014-0269-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Discovery of a highly potent glucocorticoid for asthma treatment. <i>Cell Discovery</i> , 2015, 1, .	6.7	8
2	Positioning new pharmacotherapies for COPD. <i>International Journal of COPD</i> , 2015, 10, 1427.	2.3	24
3	Fluticasone Furoate/Vilanterol: a Review of Its Use in Patients with Asthma. <i>Drugs</i> , 2015, 75, 407-418.	10.9	24
4	Fluticasone furoate/vilanterol dry-powder inhaler: a guide to its use in chronic obstructive pulmonary disease. <i>Drugs and Therapy Perspectives</i> , 2015, 31, 112-117.	0.6	1
5	Efficacy and safety of fluticasone furoate/vilanterol (50/25â€‰%mcg; 100/25â€‰%mcg; 200/25â€‰%mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized placebo-controlled trial. <i>Current Medical Research and Opinion</i> , 2015, 31, 1191-1200.	1.9	20
6	Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 743-758.	1.6	10
7	Triple inhaled therapy for chronic obstructive pulmonary disease. <i>Drug Discovery Today</i> , 2016, 21, 1820-1827.	6.4	30
8	COPD: A stepwise or a hit hard approach?. <i>Revista Portuguesa De Pneumologia</i> , 2016, 22, 214-221.	0.7	8
9	Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 167-192.	1.4	1
10	The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials. <i>Journal of Pragmatic and Observational Research</i> , 2017, Volume 8, 175-181.	1.5	18
11	Development of highly potent glucocorticoids for steroid-resistant severe asthma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6932-6937.	7.1	40
12	New possibilities of pharmacotherapy for chronic obstructive pulmonary disease. <i>Meditsinskiy Sovet</i> , 2018, , 28-37.	0.5	1
13	Fixed combination of vilanterol triphenatate/fluticasone furoate in the treatment of patients with bronchial asthma and chronic obstructive pulmonary disease: a literature review. <i>Meditsinskiy Sovet</i> , 2022, , 72-78.	0.5	0
14	Metabolically Inactivated Glucocorticoids. <i>Springer Briefs in Molecular Science</i> , 2023, , 25-36.	0.1	1